You can buy or sell Retrophin and other stocks, options, ETFs, and crypto commission-free!
Retrophin, Inc. Common Stock, also called Retrophin, is a biopharmaceutical company. Read More It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Yahoo FinanceMay 13
Retrophin Appoints Sandra E. Poole to Board of Directors
Ms. Poole brings more than 25 years of biopharmaceutical product development and manufacturing experience to Retrophin SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (RTRX) today announced the appointment of Sandra E. Poole to the Company's Board of Directors, effective immediately. Ms. Poole brings more than 25 years of biopharmaceutical industry experience in manufacturing strategy, including chemistry, manufacturing and controls (CMC), technical operations, and product development from rese...
Yahoo FinanceMay 7
Retrophin (RTRX) Reports Q1 Loss, Misses Revenue Estimates
Retrophin (RTRX) delivered earnings and revenue surprises of -75.00% and -5.72%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Yahoo FinanceMay 7
Retrophin, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 7, 2019 / Retrophin, Inc. (NASDAQ: RTRX) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 7, 2019 at 4:30 PM Eastern Time. To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/company/C-1E8A43B4CB677 To receive updates for this company you can register by emailing firstname.lastname@example.org or by clicking get investment info from the company's profile. About Investor Network Invest...
Expected Jul 25, After Hours